ArticleJournal of thoracic disease2026
Real-world survival outcomes following multimodal surgical treatment for stage IIIA non-small cell lung cancer.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Stage IIIA non-small cell lung cancer (NSCLC) is a heterogeneous disease, and the role of surgery within multimodality treatment remains controversial. With the emergence of immunotherapy, there is a need to re-evaluate surgical outcomes in real-world populations. This study compares overall survival (OS) between surgical and non-surgical approaches for stage IIIA NSCLC from a multicenter cohort. Methods: We conducted a retrospective cohort study of 598 stage IIIA NSCLC patients diagnosed between January 1, 2010, and June 30, 2021, across 21 Kaiser Permanente Northern California (KPNC) hospitals. Patients were categorized into surgical and non-surgical groups; the surgical group was further divided into surgery alone, surgery first (adjuvant therapy), and surgery later (neoadjuvant or perioperative therapy). Results: The surgical group had higher 5-year OS (52.6% Conclusions: Surgery, when integrated into multimodal treatment, is associated with significantly improved survival in stage IIIA NSCLC. These findings support continued consideration of surgery in appropriately selected patients and highlight the need for prospective studies to clarify its role in NSCLC management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.